Viral Vector Manufacturing Facility Pty Ltd (VVMF) announces its participation at the Bio International Conference 2025, June 16-19 2025, at the Boston Convention & Exhibition Center, USA.
VVMF will be part of the Australian Pavilion, located in Booth 335, where delegates can meet VVMF CEO, Stephen Thompson and Head of Business Development and Partnerships, Anita van der Meer, to discuss VVMF’s expertise in process development, viral vector manufacturing and the wrap-around services to leverage the advantages of the Australian biotechnology ecosystem.
VVMF’s CEO Stephen Thompson shared, “BIO International is the premier biotechnology event on the global calendar. We are eager to engage with industry professionals, forge new relationships, and showcase VVMF’s advanced capabilities in lentiviral (rLV) and adeno-associated viral (rAAV) vector process development and manufacturing”.
Committed to supporting biotech and pharmaceutical companies, VVMF delivers high-quality viral vector solutions tailored to their research, clinical, and commercial needs. Backed by leading scientific and clinical expertise, VVMF provides a strategic advantage- further strengthened by Australia’s 43.5% R&D tax incentive for eligible companies.
Schedule a meeting via the Bio International Conference one-on-one partnering platform or contact us at info@vvmf.com.au to explore how VVMF can be your trusted partner in advancing cell and gene therapies.
Unlocking the future of medicine – with strong connections built at the Bio International Convention.